Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-Tidow C; German Acute Myeloid Leukaemia Cooperative Group; Study Alliance Leukemia Investigators. Krug U, et al. Among authors: sauerland mc. Lancet. 2010 Dec 11;376(9757):2000-8. doi: 10.1016/S0140-6736(10)62105-8. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131036
Acute myeloid leukemia: treatment over 60.
Büchner T, Hiddemann W, Berdel W, Wörmann B, Schoch C, Löffler H, Haferlach T, Schumacher A, Staib P, Balleisen L, Grüneisen A, Rasche H, Aul C, Heyll A, Lengfelder E, Ludwig WD, Maschmeyer G, Eimermacher H, Karow J, Frickhofen N, Hirschmann WD, Sauerland MC; German AML Co-Operative Group. Büchner T, et al. Among authors: sauerland mc. Rev Clin Exp Hematol. 2002 Mar;6(1):46-59; discussion 86-7. doi: 10.1046/j.1468-0734.2002.00059.x. Rev Clin Exp Hematol. 2002. PMID: 12060483 Review.
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies.
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W. Haferlach T, et al. Among authors: sauerland mc. J Clin Oncol. 2003 Jan 15;21(2):256-65. doi: 10.1200/JCO.2003.08.005. J Clin Oncol. 2003. PMID: 12525517
6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Aul C, Gruneisen A, Lengfelder E, Frickhofen N, Kern W, Serve HL, Mesters RM, Sauerland MC, Heinecke A; German AML Cooperative Group. Büchner T, et al. Among authors: sauerland mc. J Clin Oncol. 2003 Dec 15;21(24):4496-504. doi: 10.1200/JCO.2003.02.133. J Clin Oncol. 2003. PMID: 14673036 Clinical Trial.
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Stelljes M, Bornhauser M, Kroger M, Beyer J, Sauerland MC, Heinecke A, Berning B, Scheffold C, Silling G, Buchner T, Neubauer A, Fauser AA, Ehninger G, Berdel WE, Kienast J; Cooperative German Transplant Study Group. Stelljes M, et al. Among authors: sauerland mc. Blood. 2005 Nov 1;106(9):3314-21. doi: 10.1182/blood-2005-04-1377. Epub 2005 Jul 14. Blood. 2005. PMID: 16020510 Free article. Clinical Trial.
Treatment of older patients with AML.
Büchner T, Berdel WE, Wörmann B, Schoch C, Haferlach T, Schnittger S, Kern W, Aul C, Lengfelder E, Schumacher A, Reichle A, Staib P, Balleisen L, Eimermacher H, Grüneisen A, Rasche H, Sauerland MC, Heinecke A, Mesters RM, Serve HL, Kienast J, Hiddemann W. Büchner T, et al. Among authors: sauerland mc. Crit Rev Oncol Hematol. 2005 Nov;56(2):247-59. doi: 10.1016/j.critrevonc.2004.09.010. Epub 2005 Oct 21. Crit Rev Oncol Hematol. 2005. PMID: 16246568 Review.
Treatment of AML in biological subgroups.
Buechner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Schnittger S, Kern W, Tchinda J, Reichle A, Staib P, Ludwig WD, Aul C, Sauerland MC, Heinecke A, Woermann B, Hiddemann W; German Acute Myeloid Leukemia Cooperative Group (AMLCG). Buechner T, et al. Among authors: sauerland mc. Hematology. 2005;10 Suppl 1:281-85. doi: 10.1080/10245330512331390212. Hematology. 2005. PMID: 16276628 Review. No abstract available.
Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.
Büchner T, Berdel WE, Schoch C, Haferlach T, Serve HL, Kienast J, Schnittger S, Kern W, Tchinda J, Reichle A, Lengfelder E, Staib P, Ludwig WD, Aul C, Eimermacher H, Balleisen L, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: sauerland mc. J Clin Oncol. 2006 Jun 1;24(16):2480-9. doi: 10.1200/JCO.2005.04.5013. J Clin Oncol. 2006. PMID: 16735702 Clinical Trial.
Maintenance for acute myeloid leukemia revisited.
Büchner T, Krug U, Berdel WE, Heinecke A, Sauerland MC, Wörmann B, Hiddemann W. Büchner T, et al. Among authors: sauerland mc. Curr Treat Options Oncol. 2007 Aug;8(4):296-304. doi: 10.1007/s11864-007-0041-1. Curr Treat Options Oncol. 2007. PMID: 18058075 Review.
77 results